Goldman Sachs
ABUS icon

Goldman Sachs’s Arbutus Biopharma ABUS Stock Holding History

Goldman Sachs’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.95M Buy
1,100,434
+361,854
+49% +$1.58M ﹤0.01% 3699
2025
Q4 		$3.55M Sell
738,580
-1,434,850
-66% -$6.45M ﹤0.01% 4075
2025
Q3 		$9.87M Sell
2,173,430
-866,353
-29% -$3.18M ﹤0.01% 2979
2025
Q2 		$9.39M Buy
3,039,783
+963,835
+46% +$3.2M ﹤0.01% 2818
2025
Q1 		$7.25M Buy
2,075,948
+1,544,070
+290% +$5.15M ﹤0.01% 2993
2024
Q4 		$1.74M Sell
531,878
-28,529
-5% -$105K ﹤0.01% 4402
2024
Q3 		$2.16M Buy
560,407
+403,078
+256% +$1.55M ﹤0.01% 4095
2024
Q2 		$486K Sell
157,329
-17,376
-10% -$52.1K ﹤0.01% 4846
2024
Q1 		$451K Buy
174,705
+48,115
+38% +$125K ﹤0.01% 4799
2023
Q4 		$316K Sell
126,590
-78,049
-38% -$153K ﹤0.01% 4974
2023
Q3 		$415K Sell
204,639
-17,477
-8% -$36.6K ﹤0.01% 4737
2023
Q2 		$511K Sell
222,116
-48,477
-18% -$126K ﹤0.01% 4732
2023
Q1 		$820K Sell
270,593
-113,378
-30% -$320K ﹤0.01% 4525
2022
Q4 		$895K Sell
383,971
-267,065
-41% -$639K ﹤0.01% 4492
2022
Q3 		$1.24M Sell
651,036
-80,129
-11% -$189K ﹤0.01% 4366
2022
Q2 		$1.98M Sell
731,165
-810,020
-53% -$2.07M ﹤0.01% 4064
2022
Q1 		$4.59M Buy
1,541,185
+847,914
+122% +$2.6M ﹤0.01% 3436
2021
Q4 		$2.7M Buy
693,271
+406,635
+142% +$1.58M ﹤0.01% 3985
2021
Q3 		$1.23M Buy
286,636
+182,152
+174% +$607K ﹤0.01% 4589
2021
Q2 		$317K Buy
104,484
+59,845
+134% +$185K ﹤0.01% 5487
2021
Q1 		$149K Sell
44,639
-14,611
-25% -$56.4K ﹤0.01% 5743
2020
Q4 		$210K Sell
59,250
-194,865
-77% -$682K ﹤0.01% 5067
2020
Q3 		$795K Sell
254,115
-1,410,216
-85% -$4.29M ﹤0.01% 4231
2020
Q2 		$3.03M Sell
1,664,331
-273,998
-14% -$448K ﹤0.01% 3162
2020
Q1 		$1.96M Buy
1,938,329
+1,852,238
+2,151% +$5.01M ﹤0.01% 3321
2019
Q4 		$239K Sell
86,091
-18,137
-17% -$29.3K ﹤0.01% 4833
2019
Q3 		$159K Sell
104,228
-96,508
-48% -$166K ﹤0.01% 4880
2019
Q2 		$418K Sell
200,736
-19,914
-9% -$50.9K ﹤0.01% 4470
2019
Q1 		$790K Buy
220,650
+133,253
+152% +$512K ﹤0.01% 4186
2018
Q4 		$334K Sell
87,397
-3,195
-4% -$15.7K ﹤0.01% 4583
2018
Q3 		$856K Sell
90,592
-262,746
-74% -$2.61M ﹤0.01% 4133
2018
Q2 		$2.58M Buy
353,338
+246,668
+231% +$1.47M ﹤0.01% 3459
2018
Q1 		$533K Buy
106,670
+52,148
+96% +$276K ﹤0.01% 4455
2017
Q4 		$275K Buy
+54,522
New +$320K ﹤0.01% 5223
2017
Q3 		– Sell
-91,706
Closed -$330K – 6627
2017
Q2 		$330K Sell
91,706
-149,970
-62% -$516K ﹤0.01% 5428
2017
Q1 		$785K Sell
241,676
-122,470
-34% -$340K ﹤0.01% 4604
2016
Q4 		$892K Sell
364,146
-246,302
-40% -$717K ﹤0.01% 4554
2016
Q3 		$2.1M Sell
610,448
-70,098
-10% -$274K ﹤0.01% 3794
2016
Q2 		$2.37M Sell
680,546
-68,185
-9% -$289K ﹤0.01% 3469
2016
Q1 		$3.09M Buy
748,731
+73,675
+11% +$263K ﹤0.01% 3112
2015
Q4 		$3M Sell
675,056
-29,529
-4% -$162K ﹤0.01% 3280
2015
Q3 		$4.29M Sell
704,585
-68,993
-9% -$612K ﹤0.01% 3014
2015
Q2 		$9.18M Buy
773,578
+282,796
+58% +$4.3M ﹤0.01% 2407
2015
Q1 		$8.57M Buy
+490,782
New +$10.1M ﹤0.01% 2431
2014
Q4 		– Sell
-9,512
Closed -$201K – 7093
2014
Q3 		$201K Buy
9,512
+5,445
+134% +$88.9K ﹤0.01% 6160
2014
Q2 		$53K Sell
4,067
-6,143
-60% -$87.1K ﹤0.01% 6742
2014
Q1 		$219K Sell
10,210
-4,347
-30% -$78.1K ﹤0.01% 6004
2013
Q4 		$116K Buy
+14,557
New +$121K ﹤0.01% 6223

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Goldman Sachs's ABUS Position: Q1 2026 in Review

Goldman Sachs increased its Arbutus Biopharma (ABUS) stake by 49% in Q1 2026, buying an estimated $1.58M and bringing the position to 1,100,434 shares worth $4.95M. The position accounts for ﹤0.01% of the portfolio, ranked #3699.

Goldman Sachs first reported a position in ABUS in Q4 2013 and has held it in 48 quarters since. The position peaked at $9.87M in Q3 2025. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

  • Goldman Sachs held 1,100,434 shares of Arbutus Biopharma worth $4.95M as of Q1 2026.
  • Goldman Sachs bought 361,854 Arbutus Biopharma shares in Q1 2026, an estimated $1.58M.
  • Arbutus Biopharma made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3699 holding.
  • Goldman Sachs first reported a position in Arbutus Biopharma in Q4 2013 and has held it in 48 quarters since.
  • Goldman Sachs's Arbutus Biopharma position peaked at $9.87M in Q3 2025.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.